# Study to Evaluate the Efficacy and Safety of Telmisartan/Amlodipine/Rosuvastatin

> **NCT03088254** · PHASE3 · COMPLETED · sponsor: **Jeil Pharmaceutical Co., Ltd.** · enrollment: 126 (actual)

## Conditions studied

- Dyslipidemia With Hypertension

## Interventions

- **DRUG:** Group I (Telmisartan 80 mg, Amlodipine 10 mg, Rosuvastatin 20 mg)
- **DRUG:** Group II (Telmisartan 80 mg, Amodipine 10 mg, Rosuvastatin placebo)
- **DRUG:** Group III (Telmisartan 80 mg, Amlodipine placebo, Rosuvastatin 20 mg)

## Key facts

- **NCT ID:** NCT03088254
- **Lead sponsor:** Jeil Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-20
- **Primary completion:** 2017-07-31
- **Final completion:** 2017-12-04
- **Target enrollment:** 126 (ACTUAL)
- **Last updated:** 2018-07-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03088254

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03088254, "Study to Evaluate the Efficacy and Safety of Telmisartan/Amlodipine/Rosuvastatin". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03088254. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*